BIOADAPTIVES, INC.
Close on Oct 19, 2026
- Market cap
- $478.03K
- P/E (TTM)
- –
- Dividend yield
- –
About Bioadaptives
Pharmaceutical Preparations, SIC 2834
BioAdaptives, Inc. researches, develops, markets, and distributes natural nutraceutical products and medical devices designed to support human and animal health. Its portfolio features plant-, fungal-, and algal-based dietary supplements targeting cognitive enhancement, regenerative wellness, and weight management, with brand offerings including MyndMed, Xcellara, Zeranovia, Wynovia, and PawPa Regen canine chews. The company also distributes the Lung Flute, an FDA-cleared respiratory medical device. BioAdaptives serves consumers directly through digital marketing channels and reaches patients via partnerships with telehealth platforms, medical communities, pharmacies, athletic clubs, and senior living communities.
The company operates primarily within the United States while pursuing international expansion for its respiratory device line, sourcing raw ingredients worldwide from sustainable agricultural suppliers. BioAdaptives conducts business through outsourced manufacturing and research partners, maintaining a single corporate office location. The company maintains its corporate headquarters at a single facility located in Las Vegas, Nevada.
Summary of the business section of Bioadaptives's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BIOADAPTIVES, INC.
- Founded
- 2013
- Headquarters
- Las Vegas, NV
- Address
- 2620 Regatta Drive, Suite 102 89128
- Phone
- (702) 659-8829
- Website
- bioadaptives.com
- Employees
- 1, Dec 31, 2015
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BOLADALE LAWAL & CO., Lagos, Nigeria
Stock & identifiers
- Ticker
- BDPT
- Exchange
- OTC
- IPO date
- Jul 9, 2014
- Shares outstanding
- 197M, Aug 13, 2026
- Public float
- $252.18K, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 2-for-1, Jan 23, 2025; 1-for-300 reverse, Nov 21, 2024
- SEC CIK
- 1575142
- EIN
- 46-2592228
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mark P. Frissora | Director | – |
| Gimhana Sasanka Dissanayake | Director | 125,000 |
Employees
Headcount reported in annual reports
“As of April 14, 2016, the Company had 1 full-time employee and no part-time employees.”
Corporate history
Events identified from SEC filings